PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy

First and only at home treatment approved for SMA Proven efficacy in adults and children with SMA 2 months and older SOUTH PLAINFIELD, N.J., March 30, 2021 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today anno... Biopharmaceuticals, Regulatory PTC Therapeutics, Evrysdi, risdiplam, spinal muscular atrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news